NT-proBNP, IL-1RL Can Identify High-Risk Congenital Heart Disease in Neonates

Follow Drugslib on

Medically reviewed by Carmen Pope, BPharm. Last updated on June 24, 2024.

By Elana Gotkine HealthDay Reporter

MONDAY, June 24, 2024 -- Automated quantitative tests for NT-proBNP and interleukin 1 receptor-like 1 (IL-1 RL1) can identify high-risk congenital heart disease (CHD) in newborns, according to a study published online June 24 in JAMA Network Open.

Henning Clausen, M.D., from Lund University in Sweden, and colleagues examined the performance of two diagnostic tests using minimal amounts of dried blood spots (DBS) to identify high-risk CHD in a Swedish cohort of neonates. Automated quantitative tests for NT-proBNP and IL-1 RL1 (formerly known as soluble ST2) were compared against established CHD screening methods among 313 newborns.

The DBS samples analyzed included 217 CHD cases and 96 controls; of the CHD cases, 89.3 percent (188 cases) were high-risk types, of which 38.8 percent (73 cases) were suspected prenatally. The researchers found that 94 (50.0 percent) of the high-risk cases passed pulse oximetry screening and 36 (19.1 percent) were discharged after birth without diagnoses. Compared with existing screening methods, combining NT-proBNP and IL-1 RL1 tests performed well, enabling additional identification of asymptomatic babies, with a receiver operating characteristic area under the curve of 0.95.

"Tests were accurate and performed well in differentiating healthy controls from high-risk CHD cases," the authors write. "This warrants prospective evaluation to improve early diagnosis of CHD in this vulnerable population of newborns."

Two authors disclosed ties to the pharmaceutical industry; one reported having a patent pending for screening products.

Abstract/Full Text

Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.

Source: HealthDay

Posted : 2024-06-25 03:15

Read more

Disclaimer

Every effort has been made to ensure that the information provided by Drugslib.com is accurate, up-to-date, and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. Drugslib.com information has been compiled for use by healthcare practitioners and consumers in the United States and therefore Drugslib.com does not warrant that uses outside of the United States are appropriate, unless specifically indicated otherwise. Drugslib.com's drug information does not endorse drugs, diagnose patients or recommend therapy. Drugslib.com's drug information is an informational resource designed to assist licensed healthcare practitioners in caring for their patients and/or to serve consumers viewing this service as a supplement to, and not a substitute for, the expertise, skill, knowledge and judgment of healthcare practitioners.

The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective or appropriate for any given patient. Drugslib.com does not assume any responsibility for any aspect of healthcare administered with the aid of information Drugslib.com provides. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.

Popular Keywords